Mexico office to bolster CRO Eurotrials' presence in Latin America

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Wavebreakmedia
Image: iStock/Wavebreakmedia

Related tags: Clinical research, Contract research organization, Clinical trial

Eurotrials has opened an office in Mexico City in a bid the dominant CRO in the growing Mexican clinical research market.

The Portugal-based contract research organisation (CRO) already has a strong presence across Latin America, with offices in Brazil, Argentina, and Chile, but this new office dedicated to full-service clinical operations helps tap the burgeoning Mexican market, the firm said.

“The Mexico clinical research and innovation market is becoming more dynamic due to the authorities’ willingness to make the country more attractive for R&D Investment,”​ a Eurotrials spokesperson told Outsourcing-Pharma.

“The country presents many advantages like a very good geographical location, the increasing of clinical research centres capabilities and qualified professionals in the field.”

Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) regulates clinical trials in the country, and in 2014 reduced the pre-approval time for clinical trials from three months to one month by decentralising clinical investigation protocols, according to a BMI Research report.

Moreover, the cost of running clinical trials in Mexico is less than in the US, and the country’s mainly-centralised population of 100 million is a further benefit for trial coordinators.

The office will become one of Eurotrials’ six main sites – the others being Brazil, Argentina, Chile, Portugal and Spain – and will specialise in strategic consulting, clinical studies conduct, project management and outcome research.

“Eurotrials has being working in Mexico since 2011,”​ we were told, and “making the decision to open an office for the region [presents] great opportunities for growth. This reflects Eurotrials’ approach to become a reference in the market of clinical research in Mexico.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars